Talphera Inc. (TLPH) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Talphera Inc. stock $0.45, price $0.86, that is 47.9% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Talphera Inc.
TLPH · USFar too expensive (fair value 48% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.3900 – $23.40 · fair‑value band $0.3365 – $0.5609 · the $0.8609 price screens above the $0.4487 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Talphera is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Show moreShow less
The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Stock analysis
Talphera Inc. (TLPH) currently trades at $0.8609, while our estimate is $0.4487, 48% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.3365 (bear) to $0.5609 (bull), the price of $0.8609 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Talphera Inc. reported revenue of $28.0K in FY2025 versus $378K in FY2021, a compound −47.8%/yr. Reported net income was −$14.3M in FY2025.
Key figures
Market cap $65.0M Micro · EPS (TTM) $−0.2600 · Return on equity −143% · Return on assets (EBIT) −55.6% (5-year average) · Operating margin −1,474,700% · Free cash flow −$11.4M · Net debt $605K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −48%, TLPH screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- BuyVincent J. AngottiCHIEF EXECUTIVE OFFICER, Director2× since Feb 12, 2026: 318,674 shares, avg. $0.6627$211,198Mar 13, 2026
- BuyBadri N DasuChief Engineering Officer35,000 shares at $0.8100$28,350Feb 12, 2026
- BuyRaffi AsadorianChief Financial Officer45,000 shares at $0.8100$36,450Feb 12, 2026
- BuyShakil AslamChief Medical Officer35,000 shares at $0.8100$28,350Feb 12, 2026
Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
TLPH screens overvalued: fair value 48% below the price. Compare with Merck KGaA →
Compare Talphera Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs TLPH |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs TLPH |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs TLPH |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs TLPH |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs TLPH |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs TLPH |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs TLPH |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs TLPH |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs TLPH |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs TLPH |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Talphera Inc. (TLPH) overvalued or undervalued?
What is the fair value of TLPH?
What is the quality score of TLPH?
What is the price target for Talphera Inc. (TLPH)?
What is the Talphera Inc. stock forecast for 2026?
What is the intrinsic value of Talphera Inc. (TLPH)?
Is Talphera Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of TLPH?
How much is Talphera Inc. worth?
What do the bullish and bearish scenarios say about TLPH?
How solid is the balance sheet of Talphera Inc. (TLPH)?
How far is TLPH from its 52-week high?
Which stocks are comparable to Talphera Inc.?
Is Talphera Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Talphera Inc. (TLPH)?
What should I pay attention to with Talphera Inc. right now?
Key figures of Talphera Inc.
How large is the market capitalisation of Talphera Inc. (TLPH)?
What are the earnings per share of Talphera Inc. (TLPH)?
What is the return on equity of Talphera Inc. (TLPH)?
What is the EBIT return on assets of Talphera Inc. (TLPH)?
What is the operating margin of Talphera Inc. (TLPH)?
How much free cash flow does Talphera Inc. (TLPH) generate?
How much net debt does Talphera Inc. (TLPH) carry?
Watch Talphera Inc. in the live analysis
One click puts Talphera Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.